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We sought to determine whether cognitive function in stable outpatients with heart
failure (HF) is affected by HF severity. A retrospective, cross-sectional analysis was
performed using data from 2, 043 outpatients with systolic HF and without prior
stroke enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction
(WARCEF) Trial. Multivariable regression analysis was used to assess the
relationship between cognitive function measured using the Mini-Mental Status
Exam (MMSE) and markers of HF severity (left ventricular ejection fraction [LVEF],
New York Heart Association [NYHA] functional class, and 6-minute walk distance).
The mean (SD) for the MMSE was 28.6 (2.0), with 64 (3.1%) of the 2,043 patients
meeting the cut-off of MMSE ,24 that indicates need for further evaluation of
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cognitive impairment. After adjustment for demographic and clinical covariates,
6-minute walk distance (b-coefficient 0.002, p,0.0001), but not LVEF or NYHA
functional class, was independently associated with the MMSE as a continuous
measure. Age, education, smoking status, body mass index, and hemoglobin level
were also independently associated with the MMSE. In conclusion, six-minute walk
distance, but not LVEF or NYHA functional class, was an important predictor of
cognitive function in ambulatory patients with systolic heart failure.
Introduction
Reduced cognitive function is common in patients with heart failure,[1–9] and
the ensuing impairment of executive function, memory and attention can
adversely affect patients’ quality of life and capacity for self-care. [8, 10] In
addition to comorbidities such as hypertension and diabetes and psychosocial
factors such as depression, [11] decreased cerebral perfusion due to cardiac
dysfunction has been proposed as a key mechanism for the association between
heart failure and cognitive impairment.[2, 3, 10–12] Supporting this hypothesis,
imaging studies have demonstrated organic changes in brain areas responsible for
cognitive and executive functions in patients with heart failure, [13] and have
shown that cardiac index is negatively associated with markers of brain aging in
healthy individuals. [12] Furthermore, it has been suggested that heart failure
severity can be an important predictor of cognitive function. [2, 5, 6, 10] However,
many of these studies have important limitations, including small sample sizes [5]
and potential confounding due to the restriction of enrollment to hospitalized or
elderly individuals. [1, 2, 4, 6, 7] A better understanding of how heart failure status
affects cognitive function is thus needed, and can potentially provide insights to
improve chronic management of heart failure.
The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF)
trial, [14] which followed a broad range of individuals with medically managed
chronic systolic heart failure who were in sinus rhythm, provides a unique
opportunity to address this gap in knowledge. We undertook the present analysis
of the WARCEF trial to characterize the predictors of cognitive status as measured
by the Mini-Mental State Examination (MMSE), and to determine whether there
is an independent association between cognitive function and measures of heart
failure severity, as measured by left ventricular ejection fraction (LVEF), New
York Heart Association (NYHA) functional class, and 6-minute walk distance.
Methods
The protocol for the randomized, double blinded WARCEF trial (http://www.
ClinicalTrials.gov No. NCT00041938) has been described previously. [14, 15]
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Briefly, patients with left ventricular ejection fraction (LVEF) #35% and who
were in sinus rhythm at time of enrollment were randomized to receive warfarin
(target INR 2.75, with acceptable target range of 2.0 to 3.5) or aspirin (325 mg
daily). Additional eligibility criteria included being 18 years or older, having no
contraindications to warfarin therapy, having a modified Rankin score of 4 or less
(on a scale of 0 to 6, with higher scores indicating more severe disability), and
treatment with a beta blocker, an angiotensin-converting-enzyme (ACE) inhibitor
or angiotensin-receptor blocker (ARB), or hydralazine and nitrates. Patients were
excluded if they had a clear indication for warfarin or aspirin, or if they had a
condition that conferred a high risk of cardiac embolism, such as atrial
fibrillation, a mechanical cardiac valve, endocarditis, or an intracardiac mobile or
pedunculated thrombus. Patients were also excluded if they were unable to follow
an outpatient study protocol, or if they were unable to provide informed consent.
Patients in any NYHA functional class were eligible, although patients in NYHA
class I could account for no more than 20% of the total sample. A total of 2,305
participants were recruited from 168 centers in 11 countries from October 2002 to
January 2010. The investigation conforms with the principles outlined in the
Declaration of Helsinki, [16] and the study was approved by Institutional Review
Boards at the coordinating centers for all sites. All subjects provided informed
consent. For this analysis, we further excluded 248 participants with prior
ischemic stroke, and 14 others who did not have complete MMSE assessment. The
final sample for analysis thus included 2,043 participants.
Cognitive Function, Heart Failure Severity, and Other Covariates
All data used for this analysis were collected at time of enrollment for the
WARCEF trial. The primary outcome of this post hoc analysis was cognitive
function using the MMSE at the time of enrollment. The MMSE is a brief,
validated, 30-point questionnaire commonly used to screen for cognitive
impairment. [17] In the WARCEF trial, the MMSE was administered in a
standardized fashion in the native language of each participant by trained staff at
each individual site. Importantly, results of the MMSE were not directly used to
determine patient eligibility for the WARCEF trial.
For this analysis, measures of heart failure severity included LVEF (measured by
quantitative echocardiography or radionuclide or contrast ventriculography), 6-
minute walk distance, [18, 19] and NYHA functional class. LVEF measurements
were obtained by central reading of tests performed at participating study sites by
experienced observers blinded to randomization status of trial participants. For
each participant, 6-minute walk distance was obtained by study coordinators who
measured distance walked over a 6-minute period following a standardized
protocol, [18] and NYHA functional class was determined on the basis of self-
reported symptoms by investigators at each study site.
Additional baseline demographic covariates that were collected include age, sex,
and education level (dichotomized for the current analysis as less than high school
or high school graduate and above). Health behaviors were assessed by self-report
Cognitive Function in the WARCEF Trial
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at time of enrollment, including smoking status (never, former, or current
smokers) and alcohol consumption (never, former consumption of .2 oz/day, or
current consumption of .2 oz/day). Clinical covariates were determined at the
initial study visit, including medical comorbidities (history of atrial fibrillation,
hypertension, diabetes mellitus, ischemic cardiomyopathy), medications (beta-
blockers and ACE-inhibitors/ARBs), body mass index (weight in kilograms
divided by height in meters squared), baseline systolic blood pressure, and serum
creatinine and hemoglobin levels (measured within 30 days of study enrollment).
Statistical Analysis
Descriptive statistics were provided for baseline MMSE, heart failure severity
measures, and demographic and clinical covariates described above. We further
calculated the proportion of patients with a MMSE of ,27, the cut-off for
abnormal cognitive function, and the proportion of patients with a MMSE of
,24, a cut-off commonly used to indicate need for further evaluation of
significant cognitive impairment. [20] For subsequent regression analyses, the
MMSE was treated as a continuous variable as it was clustered around higher
scores in the WARCEF population. Univariable regression analysis was performed
with the MMSE as the dependent variable and individual predictors, including
heart failure severity measures and other demographic and clinical covariates, as
independent variables. Subsequently, all predictors were entered into a multiple
regression model with the MMSE as the dependent variable. For all regression
analyses, NYHA functional classes III and IV were combined due to the small
number of participants with NYHA functional class IV. For continuous
covariates, the regression b-coefficient represents the expected point-increase in
mean MMSE for every one-unit increase of the covariate. For categorical
covariates, the regression b-coefficient represents the difference in mean MMSE
between the current category and the reference category. There was 9% (180/
2043) missing data on 6-minute walk distance, 8% (166/2043) on hemoglobin,
and 3% (58/2043) on hypertension; less than 10 values were missing on all other
variables. Therefore, multiple imputation was used to account for missing
covariate data. Specifically, we created five data sets using a sequential regression
imputation method, [21] performed regression analyses on each data set, and
subsequently combined the results to produce the reported regression b-
coefficients and t-test based 95% confidence intervals and p-values using the
method described by Rubin. [22] All statistical analyses were performed using SAS
software (version 9.2; SAS Institute, Cary, NC).
Results
Among the 2,043 WARCEF patients included in this analysis, the mean (SD) age
was 60.8 (11.3) years, and 1634 (80%) were male. Other demographic and clinical
Cognitive Function in the WARCEF Trial
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covariates are described in Table 1. Of note, a high proportion of participants
were treated with evidence-based heart failure therapy, including 90.3% who were
on beta-blockers and 98.5% who were on ACE-inhibitors or ARBs.
Table 1. Baseline characteristics of participants in the WARCEF trial included for analysis.
All patients (N52043)
Cognitive function
MMSE, score 28.6 (2.0)
Cognitive impairment (MMSE,24) 64/2043 (3.1%)
Cognitive impairment, adjusted for education* 29/2043 (1.4%)
Heart Failure Severity Measures
Ejection fraction, % 24.6 (7.6)







Age, years 60.8 (11.3)
Male gender 1634/2043 (80.0%)
High school graduate or greater 1147/2039 (56.3%)
Smoking status
Current smoker 352/2042 (17.2%)
Former smoker 1054/2042 (51.6%)
Alcohol consumption
Current consumption,.2 oz per day 517/2042 (25.3%)
Previous consumption,.2 oz per day 433/2042 (21.2%)
Medical comorbidities
History of atrial fibrillation 77/2041 (3.8%)
Hypertension 1186/1985 (59.8%)
Diabetes Mellitus 616/2040 (30.2%)
Ischemic cardiomyopathy 878/2039 (43.1%)
Body mass index, kg/m2 29.2 (6.0)
Systolic blood pressure, mmHg 123.5 (18.6)
Serum creatinine, mg/dL 1.2 (0.3)
Hemoglobin, g/dL 14.1 (1.5)
Heart Failure Medication
Beta blocker 1843/2042 (90.3%)
ACE-inhibitor or ARB 2011/2041 (98.5%)
Values are expressed as mean (SD) or number (%), where appropriate.
*Cognitive impairment adjusted for education is defined as a MMSE score of ,20 for patients with less than
high school education, or ,24 for high school graduates or above.
Abbreviations: MMSE, Mini-Mental State Examination; NYHA, New York Heart Association Class; ACE,
angiotensin converting enzyme; ARB, angiotensin receptor blocker.
doi:10.1371/journal.pone.0113447.t001
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Cognitive Function and Heart Failure Severity
The distribution of the MMSE scores was skewed towards higher values, as shown
in Figure 1. 228 (11.2%) of 2043 patients had MMSE score of ,27, suggestive of
abnormal cognitive function, while 64 (3.1%) patients had MMSE score of ,24,
indicating need for further evaluation of significant cognitive impairment. [20]
For heart failure severity, the mean (SD) for LVEF was 24.6% (7.6%), and the
mean (SD) distance for the 6-minute walk test was 356 meters (150 meters).
Slightly more than two thirds of participants were in NYHA class I or II, with
most of the remainder having NYHA class III symptoms. (Table 1).
Univariable and Multivariable Determinants of Cognitive Function
In univariable regression analysis, the MMSE score was significantly associated
with both 6-minute walk distance (b-coefficient 0.002, p,0.0001) and having
NYHA class III or IV symptoms (b-coefficient 20.460, p50.001), but not LVEF
(b-coefficient 0.006, p50.264) (Table 2). Other predictors that were significant in
univariable models included age, high school education or above, current or
former smoking, current alcohol consumption of .2 oz per day, hypertension,
diabetes mellitus, body mass index, and serum creatinine and hemoglobin levels.
Figure 1. Distribution of the Mini-Mental Status Exam scores in WARCEF patients included for analysis.
doi:10.1371/journal.pone.0113447.g001
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In the full multiple regression model, however, the only marker of heart failure
severity that independently predicted the MMSE score was increased 6-minute
walk distance (b-coefficient 0.002, p,0.0001). Increasing age remained negatively
associated with the MMSE after adjusting for other variables, while high school
education or above, higher body mass index, current or former smoking status,
and higher serum hemoglobin were positively associated with the MMSE score in
the fully adjusted model.
Table 2. Predictors of cognitive function (as measured by the Mini-Mental Status Exam) in univariable and multivariable regression models.
Univariable model (unadjusted) Multivariable model
b-coefficient (95% CI) p-value b-coefficient (95% CI)
p-
value
Heart Failure Severity Measures
Ejection fraction, % 0.006 (20.005, 0.018) 0.264 0.007 (20.004, 0.018) 0.207




II 20.128 (20.389, 0.133) 0.336 20.031 (20.286, 0.225) 0.813
III or IV 20.460 (20.741, 20.179) 0.001 20.167 (20.451, 0.117) 0.250
Demographic covariates
Age, years 20.028 (20.036, 20.021) ,0.0001 20.019 (20.027, 20.011) ,0.000-
1
Male gender 0.132 (20.082, 0.345) 0.227 20.136 (20.365, 0.092) 0.242
High school graduate or greater 0.594 (0.424, 0.764) ,0.0001 0.511 (0.342, 0.680) ,0.000-
1
Smoking status
Never smoker Ref Ref
Current smoker 0.444 (0.188, 0.699) 0.001 0.321 (0.061, 0.582) 0.016
Former smoker 0.201 (0.007, 0.394) 0.042 0.204 (0.009, 0.399) 0.041
Alcohol consumption
None Ref Ref
Current consumption,.2 oz per day 0.306 (0.100, 0.511) 0.004 0.181 (20.025, 0.386) 0.085
Previous consumption,.2 oz per day 20.035 (20.253, 0.184) 0.756 20.133 (20.355, 0.088) 0.239
Medical comorbidities
History of atrial fibrillation 20.186 (20.634, 0.263) 0.417 20.056 (20.490, 0.378) 0.801
Hypertension 20.209 (20.384, 20.035) 0.019 20.124 (20.306, 0.058) 0.182
Diabetes Mellitus 20.265 (20.451, 20.080) 0.005 20.147 (20.336, 0.043) 0.130
Ischemic cardiomyopathy 20.123 (20.295, 20.050) 0.163 0.041 (20.133, 0.214) 0.647
Body mass index, kg/m2 0.021 (0.007, 0.035) 0.003 0.015 (0.000, 0.031) 0.047
Systolic blood pressure, mmHg 0.0003 (20.004, 0.004) 0.897 0.002 (20.003, 0.007) 0.452
Serum creatinine, mg/dL 20.290 (20.552, 20.029) 0.029 0.026 (20.246, 0.298) 0.853
Hemoglobin, g/dL 0.160 (0.104, 0.215) ,0.0001 0.085 (0.026, 0.145) 0.005
For the multivariable model, the adjusted R2 was 0.073.
doi:10.1371/journal.pone.0113447.t002
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Discussion
In this retrospective, cross-sectional analysis of WARCEF participants with stable,
medically managed systolic heart failure who were in sinus rhythm and who did
not have prior ischemic strokes, we found that the only measure of heart failure
severity that was independently associated with cognitive function was the 6-
minute walk distance: LVEF and NYHA functional class were not significant
predictors of the MMSE score after adjustment for potential demographic and
clinical confounders. Furthermore, younger age and higher educational status
were both independently associated with higher MMSE scores, as was current or
former smoking, body mass index, and serum hemoglobin level.
Our study extends the literature on the relationship between heart failure status
and cognitive function. Previous studies have shown inconsistent associations
between cognitive function and measures of heart failure severity such as LVEF
and NYHA function class. [5, 6, 23] Although one study by Baldasseroni and
colleagues demonstrated a positive association between 6-minute walk distance
and cognitive function, their analysis was limited by a small sample size of only 80
elderly patients with heart failure. [24] In contrast, our analysis confirmed this
relationship in a large sample of well-characterized, stable ambulatory heart
failure patients. Furthermore, our results are also consistent with previous
observations that cardiovascular fitness and exercise capacity are important
determinants of cognitive function in both patients with heart failure [25] and the
general population. [26] Taken together, our findings suggest that the 6-minute
walk distance, which has been shown to be a powerful predictor of prognosis in
patients with heart failure, [18, 27] is an objective indicator of heart failure status
that was also strongly associated with cognitive function in this patient
population.
Reduced cardiac output leading to decreased cerebral perfusion is thought to
contribute to decreased cognitive function in patients with heart failure, [3, 12]
but it is likely that other mechanisms also play a role in the relationship between
6-minute walk distance and cognitive function that we observed in WARCEF
participants. The 6-minute walk distance integrates clinical and physiological
aspects of general fitness, and comorbidities such as hypertension, diabetes, and
atherosclerotic vascular disease could reduce both exercise capacity and cognitive
function in patients with heart failure. [11] Nonetheless, although comorbidities
such as hypertension and diabetes were associated with the MMSE for WARCEF
patients in univariable analyses, these associations were no longer significant in
the multivariable model, while the association between 6-minute walk distance
and the MMSE remained. Given the limitations of the retrospective, cross-
sectional design of the current study, future research will need to confirm our
findings and more precisely elucidate the mechanisms by which heart failure
influences cognitive function.
In addition to the expected effect of age and education, we also found that
hemoglobin level, body mass index, and current or former smoking status were
independent predictors of the MMSE in this patient population. Anemia has
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previously been shown to be associated with cognitive dysfunction in elderly
individuals. [28] Our results suggest that this relationship may also be true in
patients with heart failure, potentially representing another mechanism for the
increased risk of mortality and heart failure hospitalization conveyed by anemia
that have been well-described in this patient population. [29] Similarly, low body
mass index has been shown to correlate with cognitive decline, [30] and may
reflect cardiac cachexia and increased vulnerability to cognitive dysfunction in
patients with heart failure. It is however surprising that both current and former
smokers had higher MMSE scores compared to never-smokers in our sample, a
finding that contrasts with those from prior epidemiological studies. [31] We
speculate that this may reflect confounding of the relationship between smoking
status and the MMSE because of other factors, as current smokers were younger
and had a lower prevalence of diabetes than non-smokers in our sample, and both
current and former smokers had higher hemoglobin levels and lower systolic
blood pressure than non-smokers (data not shown).
It is worth noting that in our sample of stable outpatients with heart failure,
only a small proportion of patients had MMSE of ,27 (11.2%) or ,24 (3.1%).
These findings are in contrast to prior studies suggesting that cognitive
dysfunction could affect more than half of patients with heart failure. [1, 2, 4, 6, 9]
A likely reason for this discrepancy is that, as in other heart failure clinical trials,
most patients enrolled in WARCEF were younger than heart failure patients
followed in the community. [32] Furthermore, the exclusion from our sample of
patients who could not provide informed consent likely reduced the proportion of
patients with significant cognitive impairment. The MMSE may also be relatively
insensitive for detecting cognitive impairment in patients with heart failure, who
may often have subtle deficits in cognitive domains such as recall and executive
function. [9] Despite these limitations, however, our analysis was able to identify
that the 6-minute walk distance is an independent predictor of higher MMSE in
ambulatory heart failure patients.
There are several other limitations to our study. As a retrospective, secondary
analysis of the WARCEF trial, our results are necessarily hypothesis generating.
Since approximately 80% of WARCEF participants were male, our findings may
also not be generalizable to female patients with heart failure. Furthermore, we
analyzed data collected during the conduct of the WARCEF trial, and could not
account for psychosocial factors such as depression that could influence
assessment of cognitive function. Similarly, the WARCEF trial protocol did not
include formal neuropsychiatric testing or invasive hemodynamic assessment,
which are more definitive measurements of cognitive function and cardiac output,
respectively. We assessed cognitive function at enrollment only, and the cross-
sectional design of this analysis does not allow us to determine whether
improvement or deterioration of cognitive function may correlate with changes in
heart failure status. [10] Finally, given the WARCEF trial only included heart
failure patients in sinus rhythm, our findings cannot be extrapolated to
individuals with heart failure and other arrhythmias.
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Conclusion
In this retrospective, cross-sectional analysis of stable, medically managed
outpatients with systolic heart failure, we found that the 6-minute walk distance, a
measure of heart failure severity, was an important predictor of cognitive function
as measured by the MMSE. Our findings may be useful for future efforts to
understand and treat cognitive impairment in this patient population.
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Core Echo Lab
A.Labovitz, M. Di Tullio, M.Bierig, R. Liu, and C. Donato; Hemorrhage
adjudicator: R. Hart.
Clinical Research Organizations
Clinsys (United States and Canada): C. McKay, L. Wilson, E. Frey, K. Hayward, P.
Stein-Beal and L. Konczarek; Charite (Germany, Poland and etherlands): M. Diek,
M. Rohwedder, M. Bohdanowicz-Zazula, C.F. Peerenboom-Fey and M.
Vissiennon; Verum (Hungary and Ukraine): G. Rex, M. Varga, O. Kovtun and V.
Orlyk; FGK (Czech Republic and Slovakia): P. Arenberger and J. Jaros. STAT
Research (Argentina): A. Ruiz, M. Zimmermann and A. Ellenberg.
Complete list of WARCEF Sites
The following institutions, investigators, and coordinators enrolled patients in the
trial (shown in parenthesis is the number of patients randomized at the site):
United States, LSU Health Sciences Center (66): A. Minagar, R. Kelley, J. McGee,
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P. Jinkins, and S. Bezucha; Buffalo General Hospital (53): S. Graham, V. Hart, M.
Bonora, R. Sawyer, and K. Ammerman; Detroit VA Medical Center (50): P.
Ramappa, V. Berchou, E. Jones, and E. Olgren; Denver VA Medical Center (38):
B. Hattler, C. Anderson, B. Watson, and D. Wolf; UMDNJ - New Brunswick (29):
J. Kosits, S. Palmeri, and L. Casazza; Mayo Clinic – Transplant Center (28): D.
Yip, J. Meschia, A. McPhail, and K. Greenan; LeBauer Cardiovascular Research
(28): R. Rothbart, J. Love, T. Schrader, and V. Garman; Louisville VA Medical
Center (27): M. Stoddard, K. Remmel, and R. Longaker; UMDNJ - Newark (26):
C. Gerula, M. Klapholz, J. Kirmani, and R. Mattessich; Columbia University
Medical Center (24): M. Di Tullio, C. Rodriguez, and A. Gabriel; Reno VA
Medical Center (22): W. Graettinger, A. Baker, and A. Valencia; Madison VA
Medical Center (22): P. Kosolcharoen, and L. Williams; University of Arizona
Health Sciences Center (21): V. Sorrell, B. Coull, and D. Bruck; Morehouse School
of Medicine (20): E. Ofili, M. Frankel, and P. Jackson; Cardiac Care and Vascular
Medicine, PLLC (20): M. Nanna, J. Yasen, S. Sparr, and W. Almeida; Long Island
Jewish Medical Center (20): R. Libman, B. Stephens, and C. DeMers; Gulf
Regional Research, LLC (20): T. Giles, L. Roffidal, and D. Barratt; Veterans Affairs
Medical Center (19): M. Liston, C. Lindsey, and L. Giron; Virginia
Commonwealth University (18): W. Felton III, L. Joseph, and M. Lee; University
of Rochester Medical Center (16): J. Bisognano, C. Benesch, and L. Caufield; Santa
Clara Medical Center (16): E. Nishime, M. Moussavian, and E. Polland; Black
Hills Health Care System (16): L. Fischer, K. Peterson, and B. McGinnis; Lahey
Clinic (15): M. Tilem, G. Allam, and J. Beebe; University of North Carolina at
Chapel Hill (14): P. Chang, S. Sen, and C. Schuler; L.J. Chabert Medical Center
(14): L. Arcement, M. Charlet, and E. Falgout; Sewickley Valley Medical Group,
Cardiology (14): M. Malkowski, T. Dugan, and J. Hobbs-Williams; West Los
Angeles VA Medical Center (14): A. Warner, K. Panizzon, and J. Johnson; Albert
Einstein Medical Center (13): J. Dissin, D. Karia, and N. Molakala; Melbourne
Internal Medicine Associates (11): B. Dandapani, R. Vicari, and E. Anthony; The
Cleveland Clinic Foundation (11): I. Katzan, R. Hobbs, and A. Richmond; Denver
Health Medical Center (11): R. Hughes, W. Baker, and M Applegate; Penn
Presbyterian Medical Center (11): B. Drachman, S. Khella, and S. Donovan;
Brooke Army Medical Center MCHE - MDC Cardiology Service (10): A. Slim,
and D. Pearce Moore; Mount Sinai Medical Center (10): B. Darrow, and A.
Travis; The Westchester Medical Group (10): A. Mercando, and R. Pellegrino;
Salem VA Medical Center (10): N. Jarmukli, and T. Ochalek; St. Louis University
Hospital (9): D. Janosik, and J. Dizes; University of Kentucky (9): L.C. Pettigrew,
and D. Taylor; MetroHealth Medical Center (7): J. Hanna, and S. Bailey;
Hackensack University Medical Center (7): R. Berkowitz, and S. Mathus;
Huntington VA Medical Center (6) V. Virkud, and S. Shaw; Lehigh Valley
Hospital (6): R. Freudenberger, and S. Nabhan; Winthrop University Hospital (5):
E. Wirkowski, and B. George; Central Arkansas VA Medical Center (5): E. Smith,
and S. Locke; Connecticut Heart and Vascular Center, PC (5): C. Landau, and
D.Ferguson; University of Texas Medical School - Houston (5): H.V. Anderson,
and L. Westbrook; Cincinnati VA Medical Center (5): M. Apelian, and S. Khoury;
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Berkshire Medical Center (5): J. Leppo, and T. Bator; Richmond VA Medical
Center (4): W. Felton III, and M. Lee; University of Louisville (4): M. Stoddard,
and R. Longaker; Oklahoma City VA Medical Center (4): U. Thadani, and J.
Turner; Southern Arizona VA Health Care System (4): S. Goldman, and S.
Daugherty; Methodist Heart, Lung and Vascular Institute (4): A. Adler, and T.
Rennie; Tri-State Medical Group Cardiology (4): M. Malkowski, and D. Chupka;
George Washington University (4): R. Katz, and L. Witkin; Rochester General
Hospital (3): W. S. Burgin, and C. Weber; Penn State Milton S. Hershey Medical
Center (3): J. Boehmer, and P. Frey; Kaleida Health Millard Fillmore Hospital (3):
M. Wilson, and H. Tworek; Northport VA Medical Center (3): G. Mallis, and D.
Mauceri; Holy Cross Medical Group (3): R. Schneider, and W. Schneider; Jackson
Memorial Hospital (3): G. Ortiz, and M. Lichtenberger; Northeast Georgia Heart
Center (3): B. Hott, and D. Patrick; Rush University Medical Center (2): S.
Dunlap, and S.J. Kim; Fallon Clinic, Inc. (2): S. Pezzella, and D. Aubin; Temple
University Hospital (2): L. Nikolaidis, and J. Wong; North Shore University
Hospital (1): D. Leifer, and M. Rossi; Methodist Hospital - Physician Association
(1): G. Torre, and J. Arredondo; Mayo Clinic Scottsdale (1): J. Lynch, and A.
Metcalf; Watson Clinic Center for Research, Inc. (1): J. Gonzalez, and B. Donley;
Hospital of the University of Pennsylvania (1): T. Cappola, and K. Craig; Houston
VA Medical Center (1): B. Bozkurt, and M. Bolos; Blackstone Cardiology
Associates (1): T. Noonan, and C. Alteri; Poland, Wroclaw Military Hospital (68):
P. Ponikowski, L. Kowalczyk, A. Cwynar, D. Drazek, and J. Biegus; Specjalistyczny
Szpital im dr A. Sokoloskiego (41): R. Szelemej, M. Jurczok, R. Serafin, and A.
Jurczyk; Samodzielny Szpital Wojewodzki (33): M. Ogorek, D. Kopcik, B.
Metzkier-Wyrwa, and A. Szczepanska; The Medical University of Warsaw (22): M.
Dluzniewski, M. Modzelewski, W. Wicha, and M. Kuch; SP ZOZ Szpital
Wojewodzki (22): K. Kuc, R. Piotrowski, and O. Lesniak; Spzoz Szpital Miejski Nr
2 (15): M. Krauze-Wielicka, J. Herman, and S. Nowakowska; Miedzyleski Szpital
Specjalistyczny (15): T. Pasierski, B. Kozlowski, and K. Wolkowska; NZOZ
Poradnia Kardiologiczna Centrum-Serce (11): A. Juszczak, J. Michalska, and I.
Jedlinski; SCBK Pro Cordis (8): P. Miekus, and M. Konarzewski; SP ZOZ Klodzko
(8): P. Berkowski, and N. Jacek; Slaskie Centrum Chorob Serca (8): Z. Kalarus,
and A. Duszanska; Szpital Zespolony (5): J. Tarchalski, and P. Czaja; Medical
University of Warsaw (5): Z. Gaciong, and J. Gora; SP Szpital Wojewodzki im.
Papieza Jana Pawla II (2): A. Kleinrok, and G. Prokop-Lewicka; Canada, Ottawa
Heart Institute (41): H. Haddad, R. Davies, L. Sitwell, and J. Donaldson;
Etobicoke Cardiac Research Centre (29): T. To, R. Yufe, and B. Donelly; Montreal
General Hospital (21): T. Huynh, R. Cote, and B. St. Jacques; Brampton Research
Associates (20): D. Borts, G. Tullio, and A.M. Sindilar; Center for Neurologic
Research (19): T. Winder, E. Janzen and C. Walker; St. Michael’s Hospital (19): G.
Moe, N. Bayer, and A. Konig; London Health Sciences Centre (14): M. Arnold, D.
Spence, and J. Smith; Saint John Regional Hospital (13): R. Bessoudo, P. Bailey,
and A. McNulty; Sudbury Cardiac Research (10): S. Nawaz, and C. Dewar; QE II
Health Sciences Centre (10): M. Rajda, and M. MacFarlane; Jewish General
Hospital (6): J. Minuk, and C. Schanz; Vancouver Island.
Cognitive Function in the WARCEF Trial
PLOS ONE | DOI:10.1371/journal.pone.0113447 November 26, 2014 12 / 16
Health Research Center (6): A. Penn, and L. Atkins; Montreal Heart Institute (4):
A. Ducharme, and H. Brown; St. Boniface General Hospital (4): S. Zieroth, and A.
Mun˜oz; Netherlands, Deventer Ziekenhuis Cardiologie Research (73): D. Lok,
J.B.M. ten Holter, C. Huls, P. Bruggink-Andre, and A. van Bujisen-Nutters; Jeroen
Bosch Ziekenhuis (39): M. Daniels, A. Coppes, M.van Zagten, and N. Elzebroek;
Tweesteden Ziekenhuis (22): K. Hamroui, P. L. M. de Kort, and J. Vuijsters;
Elisabeth Ziekenhuis (16): N. Holwerda, W. Hermans, and R. van der Loo;
Medisch Spectrum Twente (14): E. Wajon, G. Hageman, and G. v. Buchem-
Damming; Reiner de Graaf Gasthuis (11): E. Ronner, A. Wissenburg-van
Lieshout, and H. Niekus; Groene Hart Ziekenhuis (9): M.W.J. van Hessen, and
G.A.M. Verheul; Twenteborg Ziekenhuis (2): G. Linssen, and L. te Pas; Ziekenhuis
Hilversum (2): J. Plomp, and P.A.R. de Milliano; Medisch Centrum Leeuwarden
(1): R. Breedveld, and M.J. Bos; Czech Republic, Kolin Hospital, Internal Dept.
(44): M. Houra, D. Beran, and R. Lebedova; Trebic Kardiologicka Ambulance
(20): J. Carda, E. Bednarova, and J. Vosmerova; Slany Municipal Hospital (17): G.
Marcinek, T. Drasnar, and O. Najmanova; Litomysl Hospital, Internal Dept. (15):
M. Dunaj, E. Pechackova, and M. Kuchar; Motol Faculty Hospital (14): P. Jansky,
J. Simon, and H. Dvorakova; Prague Cardiological Clinic (13): P. Gregor, M.
Maruskova, and L. Svoboda; Cardiology Outpatient Clinic Pilsen (13): Z. Lorenc,
and P. Kralicek; Soukroma Kardiologicka´ ambulance Opava (9): L. Pollak, Z. and
M. Krobot; Brno Faculty Hospital, Internal and Cardiological Dept. (6): J. Spinar,
and M. Nemec; St. Ann’s Hospital Brno, (5): L. Spinarova, and R. Kuba; Prague
Faculty Hospital Na Bulovce (3): F. Padour, and I. Padourova; Prague Homolka
Hospital (3): M. Padour, and M. Michalova; The Charles University Hospital (3):
L. Golan, and M. Hajkova; CARDIOMED s.r.o. (3): J. Povolny, and L. Krizova;
Liberec District Hospital (2): D. Horak, and P. Kucera; IKEM Cardiological Clinic
(2): I. Malek, and B. Krizova; Health Centre of Cardiology, Trutnov (1): J.
Svoboda, and R. Ferkl; Hungary, Karolyi Hospital (44): L. Regos, L. Csuros, O.
Lovasz, and G. Kiss; Bacs-Kiskun County Hospital (31): S. Timar, N. Torok, and
A. Hajnalne; Uzsoki Hospital (30): B. Palossy, A. Nagy, P. Fulop, and G. Jakab;
Peterfy Hospital (13): A. Ronaszeki, M. Bodi, and M. Satori; Medical and Health
Science Center, Debrecen (5): I. Edes, and I. Varga; Dr. Bugyi Istvan
Hospital (5): A. Kovacs, and L. Berente; DRC Gyo´gyszervizsga´lo´ Ko¨zpont Kft. (5):
E. Pe´terfai, and R. Pauer; Ferenc Jahn Hospital (4): K. Toth, and E. Nagy; Hetenyi
Hospital (4): B. Benczur, and K Karsay; Erzsebet County Hospital (3): T. Ve´gh,
and R. Nagy; St. Stephan Hospital (3): P. Karpati, and Z. Davidovits; National
Institute of Cardiology (2): J. Borbola, and J. Vanyi; Toldy Ferenc Hospital (2): B.
Oze and A. Bujdoso; Veszprem megyei Csolnoky Ferenc Ko´rha´z-Rendelo˝inte´zet
(1): I. Kosa, and L. Baliko; Germany, Medical Practice Dr. Natour (46): M.
Natour, M. Morgil, E. Hartmann, and H. Morgil; Ludwigshafen Clinic (18): R.
Winkler, S. Gass, and S. Baumann; Medical Practice Dr. Jeserich (18): M. Jeserich,
J. Rodl, and M. Dzaiy; Charite´ Berlin (16): S. Anker, G. Turhan, and K. Wolf;
Johannes Gutenberg University (10): S. Genth-Zotz, and T. Siebert; Medical
Practice Dr. Jakobs (9): C. Jakobs, and M. Kiorwantsi; Georg August University
(7): B. Pieske, and R. Wachter; Leipzig Medical Network (4): M. Schoenauer, and
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S. Voigt; Schleswig-Holstein University Hospital (4): H. Schunkert, and A.
Boguschewski; Regensburg University Hospital (1): M. Resch, and R. Wensel;
Gesellschaft fur Innovative Therapie (1): V. Schumann and P. Heidrich; Ukraine,
National Medical University (27): O. Girina, Y. Prokopovych, M. Lebedynska, and
I. Sorokina; City Clinical Hospital #1, Kiev (21): O. Karpenko, N. Brodi, and S.
Klochkov; M.D. Stazhesko Institute of Cardiology (17): L. Voronkov, Y. Besaga,
and O. Novikova; Kyiv Central Clinical Hospital (12): K. Amosova, O.
Yaremenko, and K. Balaban; M.D. Strazhesko Institute of Cardiology of AMS (9):
V. Kovalenko, and N. Polenova; Department Therapy of Stomatology faculty of
National Medical University (9): I. Sakharchuk, and A. Ogorodnichuk; Kiev City
Clinical Hosp of Ambulance (8): L. Rudenko, and Y. Tutov; M.D. Strazhesko
Institute of Cardiology of AMS (6): A. Parkhomenko, and S. Kozhukhov; Odessa
Municipal Clinical Hospital #9 (4): E. Yakimenko, and S. Kolomiets; Odessa
State Medical University (2): V. Yurlov, and S. Tikhonova; Argentina, Centro
Neurologico de Tratamiento y Rehabilitacion (25): C. Estol, A. Elizalde, and B.
Mangariello; CIPREC (12): C. Zaidman, and F. Guerlloy; Hospital Fernandez
(11): P. Gitelman, K. Crotto, and S. Sassone; Grupo Medico Alem (11): J. Aiub,
and F. Novoa; CICLO/Instituto de Cardiologia La Plata (10): R. Lopez Santi, and
P. Romia; CEDIMBA (Ramos Mejia) (8): O. Montan˜a, and D. Malchik; Instituto
Medico Adrogue (Centro Adrogue) (6): F. Sokn, and P. Schygiel; UAI Hospital
Universitario (5): R. Porcile, and F. Soria Tito; Instituto Cardiovascular de Buenos
Aires (2): J. Thierer, and P. Avellana; Sanatorio Itoiz, Avellaneda (2): C. Rapallo,
and M. Calderon; United Kingdom, City Hospital, Birmingham (41): R.
MacFadyen, R. Haynes, and J. Partridge; Slovakia, III. Interna klinika, FNsP
Nemocnica ak. L. De´rera (11): M. Kokles, S. Mehesˇova´, and A. Zachar;
KARDIOCENTRUM NITRA s.r.o. (11): M. Hranai, T. Varadyova, and T. Go¨bo¨;
Kardiocentrum TN sro (5): J. Litvinova, and P. Loviska.
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